We guide biotech, medtech, and pharmaceutical companies—public and private, large and small—in solving their legal problems at every stage of growth.
Life sciences and healthcare organizations depend on experienced representation in business, legal, and regulatory matters. Our biotechnology and pharmaceutical teams support clients developing and commercializing products and services that diagnose, prevent, and treat disease. We also advise clients in the medical device and medtech sectors on technologies spanning cardiovascular, diabetes, gastroenterology, imaging systems, implants, neurology, optics, pain management, renal care, stimulation devices and surgical tools.
We are an innovation partner to clients, helping them grow from the ground up to publicly traded Fortune 500 companies. Our lawyers counsel clients on intellectual property matters, fundraising, strategic alliances, collaborations, licenses, and other technology transactions, beginning with early-stage companies.
Our IP team offers boutique capabilities within a global, full-service firm. With a proven track record, we represent pharmaceutical and biotechnology clients in complex, high-stakes patent litigation in federal district courts across the United States and before the U.S. Court of Appeals for the Federal Circuit and U.S. International Trade Commission. We guide clients through inter partes review, ex parte reexamination, derivation, and interference proceedings before the U.S. Patent Trial and Appeal Board (PTAB), and we prosecute and manage patent portfolios. Furthermore, we counsel pharmaceutical companies on regulatory strategies and all aspects of the Hatch-Waxman Act and Biologics Price Competition and Innovation Act (BPCIA). Our global presence allows us to assemble strong teams around the world.
We advise healthcare providers and organizations, hospitals, insurers, research institutions, and companies throughout the industry on digital health services, FDA and controlled substance issues, transactions, managed care, litigation, operations and policy, regulatory compliance, reimbursement, data privacy and security, contracts and associated disputes, internal investigations, government audits and investigations, antitrust, taxes, M&A, and real estate.
Industry and technical strength
Our lawyers know the industry, as well as the laws and regulations that apply to it. Many of our life science lawyers have advanced degrees in various disciplines of biology, chemistry, engineering, and computer science.
Strategic advice
Ashurst Perkins Coie’s teams of lawyers, patent agents, and science advisers understand the inherent challenges of clients’ collective mission to cure disease and improve people’s health, as well as the regulations that govern these pursuits.
Advanced industry knowledge
Our areas of focus span a broad range of cutting-edge life sciences and health tech technologies. These include AI-based diagnostics and drug discovery, next-generation antibody therapeutics, biologics and biosimilars, cancer diagnostics, therapeutics, vaccines, cellular therapeutics, gene editing and gene therapy, cfDNA diagnostics and NIPT, CAR-T, T-cell receptor therapy, next-generation and third-generation sequencing, peptide therapeutics, and small molecule therapeutics.
Related insights
Carousel: clicking the "Previous" or "Next" button changes the content between the buttons.
-
Legal development
Full Court confirms Dometic: Best method assessed at filing date of divisional patent applications
April 10, 2026
Discover more -
Quickguides
Without Prejudice
Quickguide Without Prejudice
April 07, 2026
Discover more -
Legal development Supreme Court Narrows Contributory Copyright Infringement Liability for Service Providers
April 03, 2026
Discover more -
Legal development Heppner and Gilbarco: Courts Apply Privilege and Work Product Protection to Generative AI Tools
April 01, 2026
Discover more -
Legal development
Eau no! The legal reality of putting your name on the label
March 31, 2026
Discover more -
Legal development Federal Court Rules Client’s Use of Generative AI Is Not Privileged
February 27, 2026
Discover more -
Legal development
AI and Copyright: Australia Presses Pause on Reform
February 23, 2026
Discover more -
Legal development
Australia's first specific safety laws aimed at regulating the use of digital work systems
February 19, 2026
Discover more -
Legal development
PTAB Practice Under Current Leadership: Key Changes and Implications for Patent Challenges (And IPR's Still Matter!)
February 13, 2026
Discover more -
Legal development
Initial Changes To Discretionary Review of Petitions for PTAB Trials: A Preview (Part 1)
February 13, 2026
Discover more -
Legal development
How a 1960s Wiretap Law Became a Modern Legal Minefield
February 02, 2026
Discover more -
Legal development
Fed. Circ. Patent Decisions In 2025: An Empirical Review
January 22, 2026
Discover more
Related news
View allCarousel: clicking the "Previous" or "Next" button changes the content between the buttons.